Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015)

Market Cap	9.87B
Revenue (ttm)	1.46B
Net Income (ttm)	447.34M
Shares Out	70.00M
EPS (ttm)	6.39
PE Ratio	22.06
Forward PE	19.84
Dividend	3.06 (2.15%)
Ex-Dividend Date	Jul 29, 2025

Volume	20,302
Average Volume	30,411
Open	142.00
Previous Close	142.00
Day's Range	139.30 - 142.00
52-Week Range	134.00 - 183.80
Beta	0.74
RSI	41.65
Earnings Date	Feb 24, 2026

About TADAWUL:4015

Jamjoom Pharmaceuticals Factory Company, together with its subsidiaries, engages in the manufacture and distribution of pharmaceutical and consumer products in the Kingdom of Saudi Arabia, Gulf, Iraq, Egypt, North Africa, and internationally. The company offers human medicines; nutraceuticals; antibiotics; general analgesics; medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, and ulcer and acidity; treatment of various skin infections and cancer diseases; and eye drops, and ointments and cosme...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 1,129
• Stock Exchange: Saudi Stock Exchange
• Ticker Symbol: 4015

Financial Performance

In 2024, TADAWUL:4015's revenue was 1.32 billion, an increase of 19.77% compared to the previous year's 1.10 billion. Earnings were 356.52 million, an increase of 21.93%.